SDZ Share Price Performance
CHF 0
-47.83 (-100.00%)
Price CHF 0
Fair ValueCHF 70.74
Share Pricen/a
Sandoz Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 59 Fair Values set on narratives written by author
SDZ Community Narratives
AN
Fair Value
·Fair Value CHF 70.74 4.2% overvalued intrinsic discount
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
1users have liked this narrative
0users have commented on this narrative
34users have followed this narrative
AN
Fair Value
·Fair Value CHF 81.99 10.1% undervalued intrinsic discount
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value CHF 53.23 38.5% overvalued intrinsic discount
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
Sandoz sells lower-cost versions of popular medicines, but it faces a tougher road ahead as governments push harder on drug prices and new rules and lawsuits make it slower and costlier to launch products. At the same time, big investments in factories and new biosimilar launches could either strengthen its position or squeeze profits if competition heats up.Read more
AN
CHF 53.23
38.5% overvalued intrinsic discount
Fair Value
Revenue
6.65% p.a.
Profit Margin
11.89%
Future PE
19.95x
Price in 2029
CHF 59.67
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
Sandoz leans into biosimilar medicines and faster in-house manufacturing to widen its reach beyond Europe and lift profits over time. The big question is whether fierce price competition, reliance on partners, and a slower-than-hoped push in the US could hold back those gains.Read more
AN
CHF 70.74
4.2% overvalued intrinsic discount
Fair Value
Revenue
6.25% p.a.
Profit Margin
14.2%
Future PE
22.4x
Price in 2029
CHF 79.31
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
Key Takeaways Rapid biosimilars adoption and manufacturing innovation are driving above-expected revenue growth, margin expansion, and sustainable profitability. Strong presence in emerging markets and expanding product pipeline enable diversified, resilient growth and long-term earnings acceleration.Read more
AN
CHF 81.99
10.1% undervalued intrinsic discount
Fair Value
Revenue
7.07% p.a.
Profit Margin
15.57%
Future PE
23.56x
Price in 2029
CHF 91.83
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
SDZ: Upgraded GLP-1 Ambitions Will Still Face Earnings And Multiple Pressure
Fair Value: CHF 53.23 38.5% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Mixed Rating Shifts And Biosimilar Hub Investments Will Shape Future P/E
Fair Value: CHF 70.74 4.2% overvalued intrinsic discount
34 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Fair Value: CHF 81.99 10.1% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sandoz Group AG Key Details
About SDZ
- Founded
- 1886
- Employees
- 20000
- CEO
- WebsiteView website
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
